MedTrace Logo

ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis

NCT02126670 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-02-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether or not ACT01 is effective and tolerable alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with facial and/or scalp keratosis.

Conditions

  • Actinic Keratosis

Interventions

DRUG

ACT01

DRUG

Comp01

DRUG

Comp02

DRUG

Comp03

DRUG

Comp04

Sponsors & Collaborators

  • Promius Pharma, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02126670 on ClinicalTrials.gov